BiotechTube

Placebo + Ixekizumab 80 mg Q4W + Ixekizumab 80 mg Q2W

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Psoriatic Arthritis

Conditions

Psoriatic Arthritis

Trial Timeline

Dec 31, 2014 โ†’ Jun 26, 2019

NCT ID
NCT02349295

About Placebo + Ixekizumab 80 mg Q4W + Ixekizumab 80 mg Q2W

Placebo + Ixekizumab 80 mg Q4W + Ixekizumab 80 mg Q2W is a phase 3 stage product being developed by Eli Lilly for Psoriatic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02349295. Target conditions include Psoriatic Arthritis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02349295Phase 3Completed

Competing Products

20 competing products in Psoriatic Arthritis

See all competitors
ProductCompanyStageHype Score
SonelokimabMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab + Placebo + AdalimumabMoonLake ImmunotherapeuticsPhase 2
47
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab + Placebo + RisankizumabMoonLake ImmunotherapeuticsPhase 3
72
Dose A VTX958 + Dose B VTX958 + PlaceboVentyx BiosciencesPhase 2
47
Ixekizumab + PlaceboEli LillyPhase 3
77
Ixekizumab + TirzepatideEli LillyPre-clinical
23
Ixekizumab + TirzepatideEli LillyPhase 3
77
Ixekizumab + AdalimumabEli LillyApproved
85
Alefacept + Methotrexate + PlaceboAstellas PharmaPhase 2
52
SUNPG18_07 I (Tildrakizumab 200 mg) + SUNPG18_07 II (Tildrakizumab 100 mg)Sun PharmaceuticalPhase 2/3
65
TILD sub-cutaneous (SC) injectionSun PharmaceuticalPhase 3
77
SUNPG1623 I + SUNPG1623 II + SUNPG1623 III + SUNPG1623 IV + PLACEBOSun PharmaceuticalPhase 2
52
TILD + matching placebo injectionsSun PharmaceuticalPhase 3
77
TILD + matching placebo injectionsSun PharmaceuticalPhase 3
77
Ixekizumab + AdalimumabEli LillyPhase 3
77
TirzepatideEli LillyApproved
85
GuselkumabJohnson & JohnsonApproved
85
RSS0393 ointment + RSS0393 ointment + RSS0393 ointment placeboJiangsu Hengrui MedicinePhase 2
52
SHR0302 tabletsใ€Placebo + SHR0302 tabletsใ€Placebo + PlaceboJiangsu Hengrui MedicinePhase 3
77

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85